The 13 most recent market catalysts affecting $ONC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415
Barclays analyst Etzer Darout has updated their outlook on BeOne Medicines (ONC) by raising the price target from $407 to $415 and maintaining an 'Overweight' rating. This action s…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 65
BeOne Medicines Inks Voluntary Agreement With U.S. Government To Expand Access To Cancer Drugs For American Patients
BeOne Medicines (ONC) has entered into a voluntary agreement with the U.S. Government aimed at expanding access to its innovative cancer medicines for American patients. This is a …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
BeOne Medicines' Topline Data From Second Interim Analysis of Phase 3 HERIZON-GEA-01 Trial of ZIIHERA (zanidatamab) Plus Chemo, With and Without TEVIMBRA (tislelizumab) Show Statistically Significant and Clinically Meaningful Improvement in Overall Survival Trastuzumab Plus Chemo for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma
BeOne Medicines reported highly positive results from the second interim analysis of its Phase 3 HERIZON-GEA-01 trial for ZIIHERA, both as a monotherapy with chemotherapy and in co…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454
TD Cowen analyst Yaron Werber has maintained a 'Buy' rating on BeOne Medicines (ONC) and raised the price target from $424 to $454. This action indicates a strengthened positive ou…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450
RBC Capital analyst Leonid Timashev reiterated an 'Outperform' rating for BeOne Medicines, signaling continued confidence in the company's prospects. However, the price target was …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on BeOne Medicines (ONC) and slightly increased the price target from $416 to $418. This action signals continued …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430
Guggenheim analyst Michael Schmitz maintained a 'Buy' rating for BeOne Medicines (ONC) and raised the price target from $420 to $430. This action signals continued bullish sentimen…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405
Citizens analyst Reni J. Benjamin maintained a 'Market Outperform' rating on BeOne Medicines (ONC) and raised the price target from $396 to $405. This action reflects a continued p…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
BeOne Medicines Raises FY2026 Sales Guidance from $6.300B-$6.500B to $6.600B-$6.800B vs $6.479B Est
BeOne Medicines (ONC) has raised its FY2026 sales guidance from $6.300B-$6.500B to $6.600B-$6.800B, exceeding the analyst consensus estimate of $6.479B. This upward revision indica…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 95
BeiGene Q2 Adj. EPS $3.84 Beats $1.44 Estimate, Sales $1.705B Beat $1.591B Estimate
BeiGene (ONC) reported Q2 adjusted EPS of $3.84, significantly beating the analyst consensus of $1.44 by 166.67%, and sales of $1.705 billion, surpassing the $1.591 billion estimat…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425
JP Morgan analyst Jessica Fye has maintained an 'Overweight' rating on BeOne Medicines (ONC) and raised the price target from $415 to $425. This action signals continued bullish se…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403
Barclays analyst Peter Lawson maintained an 'Overweight' rating for BeOne Medicines (ONC), signaling continued confidence in the company's long-term prospects. However, the price t…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Jefferies Upgrades BeOne Medicines to Buy, Raises Price Target to $380
Jefferies analyst Faisal Khurshid upgraded BeOne Medicines (ONC) from a 'Hold' to a 'Buy' rating and simultaneously raised the price target from $333 to $380. This action indicates…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.